BioNTech 6‑K adds Q3 2025 results, Exhibits 99.1 & 99.2, call set

Rhea-AI Filing Summary

BioNTech SE furnished a Form 6‑K announcing its third quarter 2025 financial results and corporate update. The company scheduled a conference call for 8:00 am EST on November 3, 2025 to discuss the results. A press release and presentation were provided as Exhibits 99.1 and 99.2 and are incorporated by reference. The materials are designated as furnished and not deemed filed under the Exchange Act unless specifically referenced in a future filing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2025

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On November 3, 2025, BioNTech SE (the “Company”) issued a press release announcing its third quarter 2025 financial results and corporate update and details of a conference call to be held at 8:00 am EST on November 3, 2025 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein.

The information contained in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By:

/s/ Ramón Zapata-Gomez

By:

/s/ Dr. Sierk Poetting

Name: Ramón Zapata-Gomez

Name: Dr. Sierk Poetting

Title: Chief Financial Officer

Title: Chief Operating Officer

Date: November 3, 2025

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
99.2			Third Quarter 2025: Corporate Update and Financial Results

FAQ

What did BioNTech (BNTX) file?

BioNTech furnished a Form 6‑K providing its Q3 2025 financial results and a corporate update.

When is BioNTech’s Q3 2025 conference call?

The call is scheduled for 8:00 am EST on November 3, 2025.

Which exhibits accompany the BioNTech 6‑K?

The filing includes Exhibit 99.1 (press release) and Exhibit 99.2 (presentation).

Are the exhibits considered filed or furnished?

They are furnished and not deemed filed under the Exchange Act unless expressly incorporated by specific reference.

What period do the results cover for BNTX?

The materials relate to third quarter 2025 results and a corporate update.

Will the 6‑K be incorporated into other filings automatically?

No. It will be incorporated by reference only if a future filing expressly does so.